Kailera Therapeutics, Inc. Common Stock (KLRA) — Cash Flow-to-Debt Ratio
Kailera Therapeutics, Inc. Common Stock (KLRA) has a Cash Flow-to-Debt Ratio of -0.83x as of June 2026, meaning its operating cash flow of $-77.53 Million could theoretically repay -1% of its total liabilities ($92.95 Million) in one year. See Kailera Therapeutics, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kailera Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2025–2025)
Historical debt coverage capacity for Kailera Therapeutics, Inc. Common Stock across 1 annual periods. For the full cash flow conversion analysis, see KLRA cash generation efficiency.
Annual Cash Flow-to-Debt Ratio for Kailera Therapeutics, Inc. Common Stock (2025–2025)
Year-by-year debt coverage analysis for Kailera Therapeutics, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | $-120.21 Million | $1.05 Billion | — |